Jones JA, Ruppert AS, Zhao W, Lin TS, Rai K, Peterson B, Larson RA, Marcucci G, Heerema NA, Byrd JCPatients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.Leuk Lymphoma in press 5/9/2013
Huang CC, Frankel WL, Doukides T, Zhou XP, Zhao W, Yearsley MMProlapse-related changes are a confounding factor in misdiagnosis of sessile serrated adenomas in the rectum.Hum Pathol 44(4) 480-6 4/1/2013
Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161(3) 156-64 3/1/2013
Rose JS, Serna DS, Martin LK, Li X, Weatherby LM, Abdel-Misih S, Zhao W, Bekaii-Saab TInfluence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma.Cancer 118(24) 6243-52 12/15/2012
Zhao W, Huang CC, Otterson GA, Leon ME, Tang Y, Shilo K, Villalona MAAltered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer.J Oncol 2012 957437 1/1/2012
Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CLPhase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.Clin Breast Cancer 11(4) 221-7 8/1/2011